NEWS RELEASE
- -------------
NEW BRUNSWICK SCIENTIFIC CO., INC.
BOX 4005 - 44 TALMADGE RD. - EDISON, NJ 08818-4005 - 732-287-1200
FAX 732-287-4222
INTERNET: HTTP://WWW.NBSC.COM - E-MAIL: BIOINFO@NBSC.COM
INVESTOR CONTACT:
Samuel Eichenbaum
Vice President, Finance
732.650.2500
E-mail: same@nbsc.com
FOR IMMEDIATE RELEASE
---------------------
NEW BRUNSWICK SCIENTIFIC CO., INC. ACQUIRES RS BIOTECH LABORATORY
EQUIPMENT LIMITED
EDISON, NEW JERSEY, NOVEMBER 17, 2003-New Brunswick Scientific Co., Inc.
(NASDAQ: NBSC), today announced it has acquired RS Biotech Laboratory Equipment
Ltd., a designer and manufacturer of CO2 incubators. Founded in 1991 and based
in Irvine, Scotland, RS Biotech's line of state-of-the-art incubators are sold
in more than 40 countries and have been utilized in numerous studies conducted
by life science and biotech research customers.
The company's annual sales approximate $3 million and the acquisition will be
immediately accretive to New Brunswick Scientific's earnings. Although the
terms of the acquisition were not disclosed the purchase price consisted of cash
and notes.
Malcolm McNab, Managing Director and one of the founders of RS Biotech, said:
"RS Biotech's impressive range of Galaxy CO2 Incubators adds strength and fits
naturally into the New Brunswick Scientific product portfolio. There is obvious
synergy across a wide range of activities, and considerable advantage to be
gained from complementary strengths ultimately leading to benefits for all our
customers and associated parties."
David Freedman, Chairman and Chief Executive Officer of New Brunswick
Scientific, stated: "We are very pleased to have acquired RS Biotech, as its
Galaxy CO2 Incubators represent a strong addition to our lines of biological
shakers, ultra-low temperature freezers, fermentors and cell culture equipment.
Furthermore, from a human resources point of view, the quality and talent of
their people matches well with our dedicated and experienced staff."
New Brunswick Scientific Co., Inc. designs and manufactures a wide variety of
research equipment and scientific instruments for the life sciences and holds a
minority equity position in Antyra Inc., a drug-lead-discovery operation.
This press release includes statements that may constitute forward-looking
statements made pursuant to the Safe Harbor provision of the Private Securities
Litigation Reform Act of 1995. This information may involve risks and
uncertainties that could cause actual results to differ materially from the
forward-looking statements. Although the Company believes that the expectations
reflected in such forward-looking statements are based on reasonable
assumptions, such statements are subject to risks and uncertainties that could
cause actual results to differ materially from those projected. Further
information concerning risk factors is described in the Company's Securities and
Exchange Commission filings.
--